& Kauppinen, S
Neither the Summary of Product Characteristics (SmPC) for Wegovy nor that for lisdexamfetamine lists the other as a formal contraindication, and there is no official guidance from NICE, MHRA, or the British National Formulary (BNF) prohibiting their co-administration
"As their physician, I will certainly make recommendations
LIV Body states it doesn't produce compounded medications and that you may receive medication that looks different from what's shown on the brand's website
As weve explored, for FDA-approved branded semaglutide products like Ozempic and Wegovy, the answer is a definitive no , due to their once-weekly formulation, long half-life, and the inherent risks of overdosing
The drug is often associated with gastrointestinal adverse events, thereby hindering adherence